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Abstract
Objective—The purpose of the study was to examine: (a) how patient adherence and eye drop
technique were associated with visual field defect severity and (b) how general glaucoma
adherence self-efficacy and eye drop technique self-efficacy were related to visual field defect
severity.
Design—Cross-sectional study conducted at a single private practice site.
Participants—Patients on eye drops for their glaucoma.
Methods—We measured subjects’ adherence to glaucoma medications through Medication
Events Monitoring System (MEMS) devices and assessed eye drop instillation technique by
video-recording. We measured general glaucoma medication adherence self-efficacy using a 10-
item scale and eye drop technique self-efficacy using a 6-item scale. Multivariable logistic
regression was used to analyze the data.
Main outcome measures—Visual field defect severity.
Results—Patients who were less than 80% adherent according to the MEMS caps were
significantly more likely to have worse defect severity. Patients with lower scores on the general
glaucoma medication adherence self-efficacy scale were also significantly more likely to have
worse defect severity. Eye drop technique and eye drop technique self-efficacy were not
significantly related to visual field defect severity.
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Conclusions—Eye care providers need to assess patient adherence and work with those patients
with poor adherence to find ways to improve their ability and self-efficacy in using their glaucoma
medications.
Background
Poor adherence to the prescribed glaucoma regimen has been described for many years1–3
and more recent work suggests that the correlation between a provider’s estimate of a
patient’s medication adherence and the actual measured adherence of the same patient is
quite poor.4 Accordingly, there has been an increased interest in the study of glaucoma
medication adherence.5–14 A direct association has been found between patient adherence
and patient outcomes in other chronic diseases such as diabetes, asthma, and
hypertension15–18 but, to our knowledge, very little work has examined the relationship
between glaucoma medication adherence and visual field defect severity in
glaucoma.1, 19–21
Glaucoma medication adherence can be measured in several ways, including self-report,
pharmacy refill reports, electronic monitoring, and direct observation.15 It remains unclear
which method of measuring adherence correlates best with clinically significant outcomes.
For example, Konstas et al.19 found that patients with self-reported non-adherence to their
glaucoma eye drops had worse visual field loss. Rossi et al.22 found, using an electronic
monitor of adherence, that patients with a stable visual field over a one year period had a
median adherence rate of 85% and patients who worsened had a median adherence rate of
21%. In another study, worse medication adherence as measured by electronic monitors was
associated with a trend towards worse visual field scores.21 Stone et al23 found a trend
towards better eye drop instillation technique for patients with milder glaucoma severity
Observation of eye drop instillation technique and self-reported adherence are methods of
measuring adherence that are available to the provider in a clinical setting, but self-report
often overestimates adherence.24 However, there are two instruments, the general glaucoma
medication self-efficacy scale and the eye drop technique self-efficacy scale that can easily
be used in practice.8, 25 These instruments’ scoring results have been shown to be
significantly related to actual glaucoma medication adherence and eye drop technique
respectively.25
The purpose of this study was to examine: (a) how patient adherence and eye drop technique
were associated with visual field defect severity and (b) how general glaucoma adherence
self-efficacy and eye drop technique self-efficacy were related to visual field defect severity.
Methods
Design
This study was conducted at a single private practice site and used a cross-sectional design.
All eligible patients were approached for enrollment. Charts were pre-screened by study
staff prior to the patient’s regularly scheduled appointment based on the appointment
schedule for that day. All subjects were consented prior to enrollment and the protocol
followed the tenets of the Declaration of Helsinki; the study was approved by the Southwest
Independent Institutional Review Board, Fort Worth, TX and adhered to the Health and
Insurance Portability and Accountability Act.
Procedures
During the initial visit, subjects completed a demographic questionnaire and then
demonstrated their typical eyedrop instillation technique while being video-recorded (Xacti
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C5 VPC-C5; Sanyo Electric Co. Ltd, Osaka, Japan). All subjects instilled drops from a
sterile 5 mL low-density polyethylene bottle filled with sterile artificial tears. Subjects were
issued an activated Medication Event Monitoring System (MEMS) cap device and
medication vial for each bottle of hypotensive eyedrops used. This method of assessing
adherence has been successfully used in prior research.11 All subjects were educated on the
correct use of the MEMS cap device and were instructed not to alter their usual, prescribed
treatment regimen. At the subsequent 1 month follow-up visit, subjects were given a
glaucoma medication self-efficacy questionnaire to complete and all MEMS cap devices
were checked for battery life and proper recording functions. Subjects returned all MEMS
caps at the 3 month visit and any subject without a current visual field (within 9 months of
enrollment) underwent testing at that time.
Study Population
We included all consecutive subjects with a diagnosis of glaucoma, who were using 1 or
more topical hypotensive medications in one or both eyes. Subjects were only excluded if
they did not instill their own medications, if they could not come to all follow-up study
visits, or if they had a known hypersensitivity to over-the-counter artificial tears. Subjects
were required to have had a complete ophthalmic exam within the preceding 6 months.
Measurement
Subject Characteristics—We measured both age and years of education as continuous
variables. Self-reported race was originally measured as a categorical variable and then was
dichotomized for the multivariable analyses (i.e., White, non-White). Gender was measured
as a dichotomous variable. The number of glaucoma medications a subject was taking was
measured as a continuous variable and then recoded into one versus two or more for the
multivariable analyses. Length of time with glaucoma was measured with the following
response categories: two years or less, more than two years to less than five years, five years
or more.
Visual field defects were classified as mild (mean deviation ≥ -6dB), moderate (mean
deviation < -6 but > -12dB), or severe (mean deviation ≤-12dB) according to Hodopp-
Anderson criteria.25 One visual field was used in this study, only the most recent (within 9
months of enrollment) was allowed and testing strategies varied based on what was
appropriate for the patient’s severity of defect (24-2 or 10-2) or h/o reliability (SS vs. SITA-
Fast). Only SITA strategies were used from the HVF-A machine. If a recent (9 months)
visual field was not available, the patient then completed testing during study enrollment.
The reliability parameters of less than 20% errors were used.
Eye drop instillation technique—Subjects were first escorted to a dedicated exam room
with a sink, soap, towels and mirror readily available; they were uniformly instructed to
instill the artificial tears just as they would instill their medications at home. The entire
process was digitally video-recorded. Prior to analysis of the recordings, a comprehensive
list of items associated with eye drop instillation techniques was developed, based on prior
research.23 One researcher (AS) who was unfamiliar with the subjects was trained by
another author (JS) to code and review all recordings in accordance with previous studies.
Perfect instillation technique was defined as being to instill a single drop in the eye on the
first attempt without touching one’s face, eye, or eyelid.
Medication adherence—Medication adherence over a three month period was evaluated
via electronic data from the MEMS caps system (Aradex).11 Adherence using MEMS caps
was measured using the following formula: adherence = (number of doses used during the
past three months divided by the number of prescribed doses) multiplied by 100. If the
Sleath et al. Page 3













subject was on more than one glaucoma medication, an overall percent adherence variable
was created by adding together the subject’s adherence for each glaucoma medication and
dividing it by the number of glaucoma medications the subject was using. We dichotomized
the variable because the variable was skewed towards patients being highly adherent.
Subjects were considered adherent if they used 80% or more of the prescribed doses (79.5%
or above was rounded to 80% or more) and they were classified as non-adherent if they used
less than 80% of the prescribed doses as suggested in prior research.27
Glaucoma medication self-efficacy questionnaire—A 16-item glaucoma medication
self-efficacy questionnaire was completed by the subjects. The questionnaire had two
subscales, a 10-item general glaucoma medication adherence self-efficacy scale and a 6-item
eye drop technique self-efficacy scale.25 The scale is available for public use; please contact
the first author for a copy. There were four possible response choices for the self-efficacy
items: not at all confident, somewhat confident, very confident, and does not apply. The
subscales have strong psychometric properties.8, 25 The general medication adherence self-
efficacy scale has been found to be strongly associated with adherence assessed via MEMS
caps and the eye drop technique self-efficacy scale has been found to be strongly associated
with video-taped eye drop technique.8, 25
Analysis
First, we present descriptive statistics. Second, we examined the bivariate relationships
between the variables using Pearson correlation coefficients, chi-square statistics, and t-tests.
Since 70 patients had mild defect severity, 13 had moderate defect severity, and 19 had
severe defect severity, for the multivariable analyses we recoded defect severity into a
dichotomous variable (mild versus moderate/severe) which did not change our results and
made them easier to interpret.
We conducted a multivariable logistic regression to examine how the demographic
characteristics (gender, age, race, years of education, number of glaucoma medications,
length of time with glaucoma) were associated with visual field defect severity. Next, we
added whether the patients had perfect eye drop technique according to the video-tapes and
whether the patients were 80% or more adherent to their glaucoma medications according to
the MEMS caps to the regression. In a different multivariable logistic regression we added
patient scores on the eye drop technique and general glaucoma medication adherence self-
efficacy scales instead of the objective measures of eye drop technique and adherence.
Results
One hundred and two subjects participated and their demographic characteristics are
presented in Table 1. One half of the sample was male, two-thirds were white and subjects
ranged in age from 40 to 90 years. The majority of subjects (93.1%) had glaucoma in both
eyes. Forty-eight percent of the sample used only one glaucoma medication. The majority of
subjects (69%) had mild visual field defect severity.
Eighty percent of subjects successfully instilled a drop in their eye on the first attempt as
graded in the video-recordings. Seventy percent of subjects instilled only a single drop.
Thirty-four percent of subjects touched their eye or eyelash with the eye drop bottle and
52% of subjects touched their face with the eye drop bottle. Only thirty-eight percent of the
patients had perfect drop technique in the video-recordings.
Eighty-nine percent of the patients were 80% or more adherent to their eye drops according
to the MEMS caps. Patient scores on the general medication adherence self-efficacy scale
ranged from 11 to 30 (mean= 27.64 standard deviation= 3.72). Patient scores on the eye
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drop technique self-efficacy scale ranged from 8 to 18 (mean=16.34, standard deviation=
2.20).
Table 2 presents the logistic regression results predicting worse visual field defect severity.
First, we entered just the demographic characteristics into model one. Non-white patients
were significantly more likely to have worse defect severity than White patients (odds
ratio=0.33, 95% confidence interval=0.12, 0.89). Patients on two or more glaucoma
medications were significantly more likely to have worse defect severity than patients on
one glaucoma medication (odds ratio=2.62, 95% confidence interval=1.01, 6.79).
Next, we added whether the patient had perfect eye drop technique according to the video-
tapes and whether the patient was 80% or more adherent to their glaucoma medications
according to the MEMS caps into model two. Video-taped eye drop technique was not
significantly associated with visual field defect. Patients who were less adherent had worse
visual fields than patients who were more adherent (odds ratio=0.14, 0.03, 0.81). Patient
race and whether the patient was on one versus two or more glaucoma medications were no
longer significantly associated with visual field defect once patient adherence was added
into the model. Patient race was significantly associated with adherence (Pearson chi-
square=5.51, p=0.02), which could explain why it became non-significant when adherence
was entered into the model. Whether the patients were on one versus two or more glaucoma
medication was not significantly associated with adherence (Pearson chi-square=0.67,
p=0.41).
Table 3 presents the logistic regression results predicting worse defect severity. This time
we entered the patient scores on the eye drop technique self-efficacy scale and the general
glaucoma medication adherence scale (rather than the objective measures of eye drop
technique and adherence) into the logistic regression equation after we entered the
demographic characteristics. The general glaucoma medication adherence self-efficacy scale
was significantly associated with visual field defect (odds ratio=0.17, 95% confidence
interval=0.04, 0.76).
Patients who reported higher general glaucoma medication adherence self-efficacy had
better visual fields than patients who reported lower general glaucoma medication adherence
self-efficacy. We believe the self-report measure correlated well with MEMS cap adherence
and visual field defect severity because it measured self-efficacy or self-confidence in being
adherent to glaucoma medications rather than asking them how many doses they missed.
Perhaps people are more likely to respond more honestly when they are asked how confident
they feel when it comes to adherence rather than asking them how many doses they missed.
Whether the patients were on one versus two or more glaucoma medications was not
significantly associated with glaucoma medication self-efficacy (t-test=0.86, p=0.39). The
eye drop technique self-efficacy scale was not significantly associated with visual field
defect severity.
Patient race remained significantly associated with visual field defect severity even after the
general glaucoma medication adherence self-efficacy scale scores were added into the
model. Patient race and patient scores on the general glaucoma medication adherence self-
efficacy scores were not significantly associated with each other. The number of glaucoma
medications the patient was on was no longer significantly associated with visual field
defect when the general glaucoma medication adherence self-efficacy scores were added
into the model. However, number of glaucoma medications remained close to significance
(p=0.08).
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We found that non-Whites (primarily African Americans) were significantly more likely to
be less than 80% adherent to their glaucoma medications according to the MEMS caps than
Whites. This finding is similar to those of other researchers who have found that non-Whites
are less adherent to glaucoma medications than Whites.7, 21, 28
Being non-White was also significantly related to having worse visual field defect severity
until actual adherence was controlled for in the regression equation. Providers need to work
with all patients, especially non-White patients, to try to improve adherence to glaucoma
medications to prevent further vision loss. Future research needs to test interventions that
attempt to improve patient adherence, especially in African American patients.
Patients who used two or more glaucoma medications had worse visual field defect severity
than patients on one medication. This is most likely because providers add more medications
to a patient’s regimen as their defect severity gets worse.
We also found that patient scores on the 10-item general glaucoma medication adherence
scale were strongly associated with worse visual field defect severity. The self-efficacy
instrument could be used by clinicians to identify patients who do not feel confident taking
their glaucoma medications under certain circumstances. Providers could pinpoint the
problem based on patients’ responses and help address the specific challenge.
It is interesting that actual eye drop technique and reported eye drop technique self-efficacy
were not associated with visual field defect severity. This does not mean that eye drop
technique is not important, but it does show that motivating patients to adhere to their
treatment regimens is more important than patients having perfect eye drop technique.
Providers need to educate patients on the importance of adherence and they need to work
with patients to problem solve and eliminate any barriers that patients report experiencing
when using their glaucoma medications.
It is interesting that the general medication self-efficacy measure correlated well with
MEMS cap adherence and visual field defect severity. This might be because we measured
self-efficacy or self-confidence in being adherent to glaucoma medications rather than
asking patients how many doses they missed. Perhaps people are more likely to respond
more honestly when they are asked how confident they feel when it comes to adherence
rather than asking them how many doses they missed.
This study has several limitations. First, although most subjects were willing to participate,
we did not track the characteristics of those subjects who choose not to participate in the
study. Second, the study was conducted at a single site, which may limit broad applications
of these findings. Third, the high level of adherence is this study (89% of patients were 80%
or more adherent) may have been a drawback in evaluation of the non-adherent group
(unequal sample size). Despite these limitations, the study found an association between
poor adherence to glaucoma medications and patients having a worse visual field. It also
found an association between general glaucoma medication adherence self-efficacy and
patients having a worse visual field.
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  Male 50.0 (51)
Race 67.6 (69)
  White 26.5 (27)
  Black 2.9 (3)
  Asian 2.9 (3)
  Other
Duration of glaucoma
  2 years or less 10.8 (11)
  More than 2 years to less than 5 years 16.7 (17)
  5 years or more 72.5 (74)
Eye(s) affected by glaucoma
  Right 6.9 (7)
  Left 0.0 (0)
  Both 93.1 (95)
Number of different glaucoma medications used
  One 48.0 (49)
  Two 38.2 (39)
  Three 9.8 (10)
  More than three 3.9 (4)
Visual Field Defect Severity
  Mild 68.6 (70)
  Moderate 12.7 (13)
  Severe 18.6 (19)
Range; Mean (standard deviation)
Age
  40–90 years 67.27 (11.1)
Years of education
  6–30 years 15.47 (3.69)
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Table 2
Multivariable logistic regression results predicting moderate/severe defect severity (N=102)




Age 1.04 (0.99, 1.10) 1.07 (0.99, 1.13)
Years of education 0.93 (0.81, 1.05) 0.91 (0.80, 1.05)
Gender-female 1.35 (0.53, 3.45) 1.45 (0.52, 4.01)
Race – white 0.33 (0.12, 0.89)* 0.57 (0.19, 1.66)
# glaucoma medications 2.62 (1.01, 6.79)* 2.65 (0.95, 7.36)
How long have had glaucoma 0.91 (0.46, 1.82) 1.01 (0.84, 7.72)
Video-taped eye drop technique-perfect ----- 2.55 (0.84, 7.72)
Electronically measured adherence- 80% or more ----- 0.14 (0.03, 0.81)*
*
p< 0.05
OR=odds ratio 95% CI=95% confidence interval
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Table 3
Multivariable logistic regression results predicting moderate/severe defect severity (N=102)




Age 1.04 (0.99, 1.10) 1.04 (0.99, 1.09)
Years of education 0.93 (0.81, 1.05) 0.91 (0.79, 1.04)
Gender-female 1.35 (0.53, 3.45) 2.01 (0.71, 5.70)
Race – white 0.33 (0.12, 0.89)* 0.33 (0.12, 0.92)*
# glaucoma medications 2.62 (1.01, 6.79)* 2.38 (0.88, 6.43)
How long have had glaucoma 0.91 (0.46, 1.82) 1.37 (0.59, 3.17)
Eye drop technique self-efficacy ----- 0.83 (0.20, 3.35)
General medication adherence self-efficacy ----- 0.17 (0.04, 0.76)*
*
p< 0.05
OR=odds ratio 95% CI=95% confidence interval
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